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Abstract
Gastric cancer is one of the most common gastrointestinal malignancies, known also 
for its dismal prognosis, except early cases. Despite the advances in systemic therapy, 
surgery remains the cornerstone of treatment. The majority of gastric cancers are car-
cinomas, while neuroendocrine tumours and gastrointestinal stromal tumours (GISTs) 
rank next by frequency. Tumour biology, disease course and prognosis differ amongst 
the aforementioned gastric cancers; thus, surgical treatment has to be adjusted as well. 
Accumulation of evidence ensures an individualised approach in all aspects of surgical 
treatment. Specific criteria are set to choose the best surgical treatment while maintain-
ing postoperative function and acceptable life quality. Minimally invasive techniques 
continue to gain acceptance, while usage is still highly variable. Endoscopic resection 
is suitable for very early adenocarcinomas, whereas more advanced tumours require 
standard gastrectomy. Despite the initial concerns, subtotal gastrectomy (SG) is feasible 
and safe, especially for distal adenocarcinomas. In recent years, D2 lymphadenectomies 
have become more frequent in Western countries, and evidence supports this tendency. 
Surgery for gastric neuroendocrine tumours is type-specific and will be discussed in 
detail. Gastrointestinal stromal tumours are treated by local resection without wide mar-
gins or extensive lymph node dissection. Novel targeted therapy can aid surgical treat-
ment by downstaging larger GISTs.
Keywords: gastric cancer, gastric carcinoma, neuroendocrine tumours, GIST, surgery, 
gastrectomy, lymphadenectomy, laparoscopy
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1. Introduction
Despite significant reduction in incidence, important advances in understanding of tumour 
biology and improvements of complex management of this disease, gastric cancer is still a 
major and in many aspects poorly resolved oncological problem. Thus, the title ‘silent killer’ 
still remains.
Gastric cancer is the fourth most common cancer and second leading cause of cancer death in 
the world, with nearly a million of new cases in 2012 [1]. There are substantial geographical 
variations in gastric cancer incidence and survival, with half of all cases diagnosed in East 
Asia (GLOBOCAN data). This is related to the prevalence of risk factors, mainly Helicobacter 
pylori infection (Table 1) [2].
Similarly, stage at diagnosis is also dependent on geographical factors and local screening poli-
cies. In most countries, the majority of cases are still diagnosed at an advanced stage (see Figure 1).
There are many classifications for gastric cancer. Anatomically, it can be divided in true gas-
tric (noncardia) cancers and gastro-oesophageal (cardia) cancers, which differ in epidemiol-
ogy and surgical treatment [1]. Histologically, the majority of gastric cancers are malignant 
epithelial tumours, namely, carcinomas (>90%), while neuroendocrine tumours (NETs) and 
gastrointestinal stromal tumours (GISTs) rank next by frequency [3].
Surgery is still the only potentially curative treatment of gastric cancer. Despite adequate sur-
gical resection, gastric cancer has a high recurrence rate after operation [4]. Survival parame-
ters have traditionally been higher in Asian countries due to screening and higher proportion 
of early disease [5]. A 5-year overall survival of 72.3% has been reported in one Korean study, 
whereas European studies report survival of 28.0–44.3% [2]. To improve these figures, a sys-
tematic and evidence-based approach must be used to treat gastric cancer.
Since gastric carcinomas, NETs and GISTs have different characteristics, natural history and 
prognosis, the cornerstone of treatment, surgical resection, has to be adjusted as well. In this 
chapter, we discuss the common features and differences in surgical treatment of different 
gastric cancers according to TNM stage as well as the latest advances in minimally invasive 
and endoscopic surgical techniques.
Risk factor Influence and relative risk
H. pylori infection ↑ 3.02
Pernicious anaemia ↑ 6.8
Cigarette smoking ↑ 1.53
Heavy alcohol consumption ↑ 1.20
High dietary salt ↑ 1.07
Dietary fruit and vegetables ↓ 0.81
Table 1. Risk factors of gastric cancer.
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2. Gastric adenocarcinomas
Carcinomas, representing malignant epithelial tumours, arise from epithelial cells in the most 
superficial, mucosal layer of gastric wall. Traditionally, carcinomas have been divided, accord-
ing to Lauren classification, in diffuse and intestinal type (Figure 2). The former is poorly dif-
ferentiated, lacks glands, has a more pronounced genetic component, spreads via transmural 
and lymphatic route and generally has a worse prognosis. Intestinal type is characterised by 
glandular structures, well or moderately differentiated tumours with haematogenous spread 
and more pronounced environmental risk factor influence [6]. More recently, the WHO pro-
duced a classification that was in concert with histological division of gut tumours—tubu-
lar, papillary, mucinous adenocarcinomas, poorly cohesive carcinoma and rare variants [1]. 
However, there is very little evidence that the aforementioned classifications have additional 
prognostic value compared to TNM staging [6]. Therefore, for this practical guide, only TNM 
stage will be taken into consideration.
Figure 1. Haematogenous spread of intestinal gastric cancer. Gastrectomy showing a dominant mass lesion. Inset: 
synchronously resected liver metastasis.
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2.1. Early gastric adenocarcinomas
For very early gastric carcinomas (T1a), endoscopic treatment is possible. Precise patient 
selection is essential to avoid suboptimal treatment. The target is to identify a subgroup of 
patients for whom the risk of lymph node metastases is virtually zero [5]. Both Japanese and 
European guidelines have similar criteria for patient selection for endoscopic treatment [5, 7]:
1. Confined to mucosa (T1a)
2. Well differentiated
3. Non-ulcerated
4. Diameter of ≤2 cm
However, in the guidelines, issued by european society for medical oncology (ESMO), these 
criteria are necessary to consider endoscopic treatment [III, B], whereas Japanese guidelines 
state them as an absolute indication for endoscopic resection [5, 7]. This underlines the experi-
ence of Japanese doctors in endoscopic treatment of very early gastric cancer. The resection 
is considered curative when a meticulous pathologic examination of specimen reveals an en 
bloc resection of a tumour with previously mentioned features, negative resection margins 
and no lymphovascular invasion [7].
Figure 2. Types of gastric carcinoma by Lauren classification. (A and B) Intestinal type: (A) gross view in gastrectomy 
and (B) morphological structure showing adenocarcinoma. Haematoxylin-eosin, original magnification (OM) 100×. 
(C and D) Diffuse type: (C) gross view in gastrectomy and (D) morphological structure showing signet ring cells. 
Immunoperoxidase, cytokeratin AE1/AE3, OM 400×.
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There are two principal methods for endoscopic removal of gastric cancer. In endoscopic 
mucosal resection (EMR), a saline injection is used to elevate the tumour and is followed by 
an excision with a snare device using electrocautery [6] (Figure 3). This is generally indicated 
for lesions smaller than 10–15 mm [5].
In endoscopic submucosal dissection (ESD), electrocautery is used to mark the borders of 
the tumour followed by hydrodissection with epinephrine and indigo carmine. The lesion is 
then removed en bloc by dissecting the submucosal layer from the proper muscle layer using 
insulation-tipped electric knife [6, 7] (Figure 4).
Figure 3. Endoscopic mucosal resection: (1) Localisation of tumour, (2) submucosal injection of saline to elevate the area 
and (3) electrocautery is applied through snare device to perform resection followed by removal of the lesion.
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A meta-analysis comparing both methods was performed, and the results indicated signifi-
cantly higher en bloc and complete histologic resection rates for ESD (odds ratio, OR = 9.69 
vs. OR = 5.66, p < 0.001). This increased radicality and also resulted in lower recurrence rate 
(OR = 0.009, p < 0.001). On the other hand, perforation rate was significantly higher for ESD 
(OR = 4.67, p < 0.001) [8]. The European Society of Gastrointestinal Endoscopy Guidelines rec-
ommend ESD as the standard procedure for most early gastric tumours [IV, B] [5].
Extended criteria for ESD also are known. One Korean study found no statistically significant 
differences in recurrence rates between absolute indication and extended indication groups 
(7.7% vs. 9.3%, p = 0.524). However, due to the lack of high-quality evidence, these indications 
remain investigational and will not be discussed in detail here [7].
Surgical resection is indicated in patients with T1 tumours that do not meet the criteria for 
endoscopic treatment. However, the extent of resection can be reduced compared to more 
advanced cancers [5]. For patients with clinical T1 and N0 who require surgical resection for 
middle gastric cancer, a pylorus-preserving gastrectomy can be offered if the distal extent of 
tumour is at least 4 cm proximal to pylorus (see Figure 5). For early proximal gastric tumours, 
proximal gastrectomy is an option if more than half of the distal stomach can be preserved 
(Figure 6) [4]. As for segmental gastrectomy and local resection under sentinel navigation, 
Figure 4. Endoscopic submucosal dissection. (1) Marking borders of the tumour with electrocautery, (2) submucosal 
injection of a lifting agent, (3) circumferential mucosal incision followed by submucosal dissection with insulation-
tipped electric knife and (4) haemostasis.
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these are still considered investigational [7]. If the above-mentioned criteria are not met, 
early gastric cancer is treated with a standard gastrectomy. In addition, lymphadenectomy 
is required because of the risk of lymph node metastases due to submucosal invasion. The 
extent of lymphadenectomy in early gastric cancer will be discussed in the following chapter.
Figure 5. Pylorus-sparing gastrectomy.
Figure 6. Proximal gastrectomy.
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Figure 7. Lymph node stations: (1) right paracardial, (2) left paracardial, (3) lesser curvature, (4sa) short gastric, (4sb) left 
gastroepiploic, (4d) right gastroepiploic, (5) suprapyloric, (6) infrapyloric, (7) left gastric artery, (8a) anterior common 
hepatic, (8p) posterior common hepatic, (9) celiac trunk, (10) splenic hilum, (11p) proximal splenic, (11d) distal splenic, 
(12a) left hepatoduodenal and (13) retropancreatic.
2.1.1. Extent of lymphadenectomy for early gastric tumours
Lymphadenectomy is an essential part of radical gastric cancer surgery. According to the latest 
UICC/AJCC TNM classification (seventh edition), at least 15 lymph nodes must be harvested 
to perform adequate staging [5]. However, in a USA-based study comprising more than 3000 
patients, it was found that only 23.8% of cases had more than 15 lymph nodes harvested [6].
All of the relevant lymph nodes are divided in 16 stations (see Figure 7). The first six sta-
tions, perigastric nodes, are grouped together as N1. Stations 7–11, coeliac axis, are grouped 
as N2 [4]. Depending on the extent of lymph node removal, the term D1 (perigastric nodes) 
or D2 (perigastric nodes plus clearance of coeliac axis) is used [5]. However, traditionally, 
the extent of lymphadenectomy was classified relative to the location of tumour [6]. In the 
latest Japanese gastric cancer treatment guidelines (2014), a more rational approach is sug-
gested. What constitutes D1 or D2 lymphadenectomy is actually dependent on the extent of 
gastrectomy, regardless of tumour location [7]. For example, in total gastrectomy (TG), D1 
means removal of the first seven nodal stations, whereas in distal gastrectomy, D1 constitutes 
removal of stations 1, 3, 4sb, 4d and 5–7 [7].
For all cT1a tumours which are not amenable to endoscopic treatment as well as cT1b 
tumours, D1 lymphadenectomy is necessary. If the tumour is well differentiated and does not 
exceed 1.5 cm in diameter, D1 lymphadenectomy is sufficient. For larger and less differenti-
ated tumours, an extended D1+ lymphadenectomy is required based on the tumour localisa-
tion and the extent of gastric resection. Several but not all of the D2 nodes are included in this 
lymphadenectomy [7].
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2.2. Gastric carcinoma stage IB–III
There is a consensus amongst specialists and societies that gastric carcinoma invading proper 
muscular layer or having positive lymph nodes requires a standard gastrectomy [4–7]. A 
standard gastrectomy means either total gastrectomy (Figure 8) or distal subtotal gastrec-
tomy removing at least two-thirds of the stomach (Figure 9) [4]. In Japanese guidelines, a D2 
lymphadenectomy is an integral part of standard gastrectomy. However, in Western coun-
tries this recommendation is not so strict. General recommendation is that a D2 dissection 
should be performed in high-volume specialised centres with appropriate experience if the 
patient is medically fit [5].
2.2.1. Extent of lymphadenectomy for stage IB–III gastric carcinoma
There used to be a fierce debate between Asian and Western surgeons about the extent of 
lymphadenectomy. Asian specialists advocated D2 lymphadenectomy because of superior 
oncologic outcomes. However, Western surgeons argued that D2 lymphadenectomy only 
added to perioperative morbidity and mortality with no significant survival benefit [4]. There 
were three randomised controlled trials (RCTs) that addressed this issue. The Dutch trial ran-
domised 711 patients in D1 and D2 lymphadenectomy groups. It has to be noted that distal 
pancreatectomy with splenectomy was performed in all cases with D2 dissection but only 
selectively in D1 dissection. This trial reported a significantly higher morbidity (42% vs. 4%, 
p < 0.001) and mortality (10% vs. 4%, p < 0.004) in D2 group. Furthermore, there was no 5-year 
survival benefit in D2 group (D1 = 34% vs. D2 = 33%). However, this study was criticised 
because of many shortcomings. One of them was the fact that surgeons participating in this 
trial had no previous experience in D2 lymphadenectomies and they were trained using video 
Figure 8. Total gastrectomy. In total gastrectomy, D1 lymphadenectomy constitutes dissection of nodal stations 1–7. D2 
lymphadenectomy constitutes dissection of D1 + stations 8a, 9, 10, 11p, 11d and 12a.
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materials and booklets. It was only after the 15-year survival data were analysed that the 
evidence showed positive results for D2 dissection. Gastric cancer-related deaths were sig-
nificantly lower in D2 group (37% vs. 48%). Local (12% vs. 22%) and regional (13% vs. 19%) 
recurrence rates were also lower in D2 group. The overall 15-year survival was 21% in D1 
group and 29% in D2, without statistically significant difference (p = 0.34) [4, 9].
Another famous study that questioned the usefulness of D2 dissection was Medical Research 
Council trial. The results of this study drew similar conclusions – there was no evidence to 
support routine use of D2 lymphadenectomy. Again, distal pancreatectomy with splenec-
tomy was performed in D2 dissections just as it was in the Dutch study. Significantly, lower 
survival on subgroup analysis was noted in both studies for patients with distal pancreatec-
tomy and splenectomy. The third landmark RCT on this subject, the Italian study, found com-
parable overall morbidity (12.0% in D1 vs. 17.9% in D2, p = 0.178) and no significant difference 
in 30-day postoperative mortality rate (3.0% in D1 vs. 2.2% in D2, p = 0.72). The essential 
difference was that only experienced surgeons participated in this trial and that distal pancre-
atectomy with splenectomy was not routinely performed [4, 9]. The main conclusion is that 
in Western countries D2 lymphadenectomy can be safely performed in high-volume centres 
by experienced surgeons. Distal pancreatectomy and splenectomy are no longer considered 
an integral part of modern D2 lymphadenectomy and are considered beneficial only if the 
primary tumour or metastatic nodes invade these organs [4, 7, 9].
2.2.2. Extent of resection
Microscopically, negative resection margins are required to qualify any gastric resection as 
curative. Although not all patients with positive resection margins develop cancer recurrence, 
Figure 9. Distal subtotal gastrectomy. In distal subtotal gastrectomy, D1 lymphadenectomy constitutes dissection of 
nodal stations 1, 3, 4sb, 4d, 5, 6 and 7. D2 lymphadenectomy constitutes dissection of D1 + stations 8a, 9, 11p and 12a.
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this undoubtedly worsens prognosis [10]. There seems to be a lack of agreement about what is 
an adequate margin from gastric carcinoma with different articles suggesting slightly differ-
ent numbers. There are studies that have illustrated tumour cell spread as far as 5 cm laterally 
from the primary tumour. Therefore, a margin of at least 6 cm seems necessary [6]. However, 
according to other experts, a 4 cm margin is sufficient [1, 4].
Discussion about distal resection margin is simpler. This margin is limited by the papilla of 
Vater and is generally 2–4 cm from the pylorus. If the tumour invades papilla or further down 
the duodenum, a metastatic disease is expected, and gastrectomy alone will not suffice [10].
Regarding proximal resection margin, the Japanese guidelines have specific recommenda-
tion. For T1 gastric carcinoma, a gross resection margin of 2 cm is recommended. In case the 
tumour margins are equivocal on preoperative endoscopy, a biopsy-guided marking with 
clips can be used to aid in intraoperative decision-making [7]. If the cancer is invading proper 
muscular layer or deeper, a 3 cm margin is needed for expansively growing tumours, and 
5 cm are necessary for infiltrating tumours [7]. The idea that optimal proximal margin dis-
tance is stage-dependent is highlighted by a multicentre US study reporting on 465 patients 
who underwent gastric resection due to distal gastric carcinoma. Authors found that in stage 
I there was no difference in overall survival between 3.1–5.0 cm and >5.0 cm proximal margin 
[11]. For a diffuse gastric carcinoma, an 8 cm margin is recommended [5]. If the resection 
margin is negative, the distance from the tumour does not per se influence the prognosis [10]. 
Therefore, in case the aforementioned criteria regarding proximal margin distance cannot be 
followed, frozen section examination is highly recommended [7]. In case of positive resec-
tion margins on the final histology, the benefits of reoperation must be weighed against the 
risks of repeated operation. Reoperation is usually warranted in low-stage cases with minimal 
(N0–N1) nodal involvement [10].
2.2.3. Total vs. subtotal gastrectomy
Unlike the debate regarding lymphadenectomy, total gastrectomy (TG) vs. subtotal gastrec-
tomy (SG) is a less polarising topic. Since the ‘en principle’ total gastrectomy was suggested in 
the 1970s, several large studies have provided evidence to support the role of distal subtotal 
gastrectomy [12]. Currently, it is the procedure of choice for early gastric cancer located in 
the distal and middle third of the stomach if the resection margins are located well within the 
healthy stomach (distances discussed previously). The advantages of subtotal gastric resection 
are the following: several studies have reported lower morbidity and mortality, reduced hos-
pital stay and superior nutritional status with better quality of life in long term [12]. Two large 
randomised trials performed in Europe found no significant difference in long-term survival 
between TG and SG for distal gastric cancer but lower morbidity, mortality and better quality of 
life in SG group [12]. A recently performed meta-analysis of six trials also found no significant 
difference in 5-year survival between TG and SG groups (p = 0.18). However, it did not show 
higher postoperative complication rates (p = 0.30) or hospital mortality (p = 0.12) in TG group 
which was in contrast to previously mentioned studies [13].
There are several proposed advantages of TG. It could reduce the risk of inadequate lymph node 
harvest, thus lowering local recurrence risk. Due to removal of all gastric tissue, it eliminates 
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the risks of multicentric synchronous or metachronous carcinoma [13]. TG is recommended 
for gastric carcinoma located in the upper third of the stomach, signet ring cell cancers (linitis 
plastica), cancer arising on the background of atrophic gastritis, multicentric cancers, advanced 
distally located tumours with lymph node metastasis to allow extended lymphadenectomy, 
invasion of pancreas (which requires pancreaticosplenectomy) and patients with inherited 
E-cadherin mutation as a prophylactic measure (due to 80% lifetime risk of developing gastric 
cancer) [1, 6, 7, 12, 13].
2.2.4. Laparoscopic vs. open gastrectomy
Laparoscopic gastric cancer surgery is technically demanding and is currently performed 
more routinely by Asian surgeons. Nevertheless, more and more specialists around the globe 
are becoming more confident in laparoscopic surgery, and, with the help of technological 
advancements, usage of laparoscopy will certainly increase [14]. As discussed previously, 
very early gastric carcinomas are preferably treated by endoscopic resection. However, crite-
ria for endoscopic treatment are very strict, and these methods are more widely used in high-
incidence countries with high proportion of early cases. Therefore, the most solid indication 
for laparoscopic surgery is gastric carcinoma located in the distal or middle third of the stom-
ach and limited to submucosa without evidence of lymph node involvement or mucosal can-
cers not amenable to endoscopic treatment [14]. In case of laparoscopic total gastrectomy, the 
more widely accepted indication is T1N0 tumour of proximal third of the stomach [14]. There 
is evidence that laparoscopy is a safe and feasible option even for advanced gastric carcino-
mas if performed in high-volume specialised centres [1]. A systematic review comprising 3411 
patients revealed similar lymph node harvest and long-term survival for laparoscopic distal 
gastrectomy compared to open approach. Hospital stay, analgetic consumption, postopera-
tive complication rate and blood loss in surgery were all reduced in laparoscopic approach 
group [1]. Surgeons in Eastern Asia have expanded the use of laparoscopy to advanced can-
cers even with limited involvement of perigastric nodes [14]. There is still a small amount of 
high-quality evidence to support these expanded indications [4, 14]. However, one large sys-
tematic review analysing 23 studies with 7336 patients was recently published. Authors found 
comparable 5-year overall survival (p = 0.45), recurrence (p = 0.08) and gastric cancer-related 
death rates (p = 0.28) between laparoscopic and open gastrectomy groups. These results led 
them to conclude that laparoscopic gastrectomy was comparable to the open approach and 
did not worsen oncologic results [15]. To evaluate the role of laparoscopy in advanced gastric 
cancer, a meta-analysis comprising 11 studies and 1904 patients was performed. A D2 dissec-
tion was performed in both open and laparoscopic cases. Researchers found reduced blood 
loss, morbidity, shorter postoperative ileus and length of hospital stay in laparoscopic group, 
although the operation time was longer by almost 42 min (p < 0.05). No significant difference 
was noted in lymph node harvest, intrahospital mortality, recurrence rate and 3-year overall 
survival rates. This indicates that laparoscopy has several advantages in short-term results 
and is equivalent from oncologic standpoint [16].
While many surgeons perform the so-called laparoscopy-assisted gastrectomy which requires 
mini-laparotomy incision and extracorporeal anastomosis, several options for totally laparo-
scopic gastrectomy are available. Even single-port laparoscopy is being performed frequently 
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in high-volume centres. A small study comparing 50 single-port laparoscopies with 50 multi-
port surgeries indicated superior short-term results for single-port surgery. However, this 
did not lead to reduced hospital stay. Most specialists use at least five ports for laparoscopic 
gastrectomy [14].
Despite the aforementioned studies, the present state of laparoscopic gastric surgery is not 
entirely clear. A lot of the evidence comes from Asian countries, high-volume specialised 
centres with considerable experience. Current studies have been criticised for bias and hetero-
geneity, for example, not including the most advanced gastric cancers in studies comparing 
open with laparoscopic approach. Some authors have found reduced lymph node harvest 
at specific nodal stations during laparoscopic D2 dissection. This has raised the question 
of robotic surgery as a valid tool to overcome some of the technical difficulties that comes 
with laparoscopic surgery. Robotic system has superior manoeuvrability and visualisation, 
which is essential in performing dissection along the celiac axis, spleen and pancreas. Another 
advantage is the relatively easier restoration of gastrointestinal continuity using robotic sys-
tem. As with other procedures, robotic gastrectomy seems to take less time to master than 
conventional laparoscopic surgery although this could in part be related to previous experi-
ence in laparoscopic approach. There is currently not enough high-quality evidence to draw 
any definitive conclusions on robotic gastric cancer surgery in comparison with conventional 
laparoscopic and open surgery [17].
3. Gastric neuroendocrine tumours (NETs)
NETs arise from the cells of the diffuse neuroendocrine system that are scattered all around 
the body and have both neural and endocrine characteristics (Figure 10). This is a heteroge-
neous group of tumours with wide variations in biologic behaviour, clinical picture and opti-
mal management. Despite the fact that these tumours are typically indolent in nature, often 
Figure 10. Gastric NET. (A) Haematoxylin-eosin, original magnification (OM) 100×. (B) Synaptophysin expression. 
Immunoperoxidase, OM 100×.
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described as slowly growing, they all have malignant potential. Therefore, surgical resection 
is the only definitive treatment [18].
Gastric NETs (GNETs) are rare tumours, but their incidence is growing. The proportion 
of GNETs amongst all gastrointestinal NETs also increases. The current incidence is 1–2 per 
100,000 persons per year which accounts for 8.7% of all gastrointestinal NETs. This increase of 
incidence is at least partly related to more widespread use of gastrointestinal endoscopy [18, 19].
There are three to four types of GNETs which differ significantly in terms of biologic behav-
iour, malignancy, prognosis and optimal treatment [18–20]. Some discrepancy in literature 
regarding classification of GNETs is noted. Although the latest European Neuroendocrine 
Tumour Society (ENETS) guidelines still divide GNETs in three types, a further subclassifica-
tion of type 3 tumours is considered appropriate [20]. A comparison of different GNET types 
is depicted in Table 2.
3.1. Type 1 GNETs
This is the most common type of GNETs (70–80%) and is more frequently seen in female 
patients. Type 1 GNETs develop from enterochromaffin-like (ECL) cells and are associated 
with chronic gastric mucosal atrophy caused by H. pylori or autoimmune gastritis. These 
tumours are well differentiated, usually small (<1 cm), multiple, located in the fundus or cor-
pus, limited to mucosa or submucosa and have an excellent prognosis [18–20]. They have a 
very low mitotic rate and metastatic potential (2–5%) [18, 19]. Pathophysiological mechanism 
of type 1 GNET development is achlorhydria caused by atrophic gastritis, which stimulates 
gastrin production, which in turn evokes ECL cell hyperplasia [19].
These tumours are best treated with conservative approach, with surgery reserved for 
selected cases. In ENETS guidelines, endoscopic surveillance every 1–2 years is recommended 
Tumour characteristics Type 1 GNET Type 2 GNET Type 3 GNET
Proportion of GNETs (%) 70–80 5–6 10–15
Associated diseases/syndromes Chronic atrophic gastritis MEN1-ZES Sporadic
Typical tumour size (cm) <1–2 cm <1–2 cm >2 cm
Tumour number Multiple Multiple Solitary
Location Fundus, corpus Fundus, corpus Any
Serum gastrin ↑ ↑ N
Histology (most common) NET G1 NET G1/G2 NEC G3
Invasion Mucosa, submucosa Mucosa, submucosa Any
Frequency of metastasis (%) 2–5 10–30 >50
Prognosis Excellent Good Poor
GNET, gastric neuroendocrine tumour; MEN1-ZES, multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome; 
N, normal; NET, neuroendocrine tumour; G, grade; NEC, neuroendocrine carcinoma.
Table 2. Features of different gastric NETs.
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for lesions <1 cm without evidence of invasion into the proper muscular layer or metastasis. 
However, other specialists have recently suggested removal of all visible lesions with biopsy 
forceps or EMR (>5 mm tumours). This approach has to be compared with the previously 
 mentioned less aggressive management in randomised trials to support its use. Any GNET 
with size close to 10 mm or threatening proper muscular layer has to be resected to avoid 
metastatic spread [18–20]. Research has shown superior complete resection rates for ESD 
compared to EMR in the treatment of GNETs [19].
Surgical resection is recommended for type 1 GNETs that are invading the proper muscular 
layer (T2), have recurred after endoscopic removal and are poorly differentiated or in case of 
positive resection margins after endoscopic resection [18–20]. Depending on the location and 
number of lesions as well as potential involvement of lymph nodes, local excision, partial or 
total gastrectomy is selected. Antrectomy to reduce hypergastrinemia is questionable and is 
rarely performed [18, 20].
3.2. Type 2 GNETs
These tumours are less frequently encountered (5–6%) and are associated with multiple endo-
crine neoplasia type 1 and Zollinger-Ellison syndrome (MEN1-ZES). Just like type 1 GNETs, 
they are gastrin-dependent, consist of ECL cells, are small, multiple and relatively benign. 
These are equally distributed amongst genders and in 10–30% of cases are metastatic at pre-
sentation. Although type 2 GNETs are asymptomatic per se, they can present with peptic 
ulcer disease due to hypersecretion of gastric acid caused by ZES [18–20].
According to the National Comprehensive Cancer Network (NCCN) guidelines, the treatment 
of type 2 GNETs is similar to type 1 tumours. In ENETS guidelines, however, only local surgical 
excision is recommended. The fact that the patient has multiple tumours does not alter surgical 
treatment by itself. Local or limited resection of the coexisting gastrinoma is recommended, but 
decision has to be made in a multidisciplinary setting in high-volume centres [18, 20].
3.3. Type 3 GNETs
Type 3 NETs (10–15%) are sporadic, usually poorly differentiated, single tumours >10 mm in size not 
associated with gastrin hypersecretion. These tumours have the tendency to invade proper muscular 
layer and are frequently metastatic (in regional lymph nodes, liver) at the time of diagnosis [18–20].
There are reports that suggest that in selected cases (<2 cm, well differentiated, submucosal, 
without lymphovascular invasion) type 3 GNETs should be treated with endoscopic or wedge 
resection. Despite that, ENETS guidelines strictly recommend type 3 GNETs to be treated like 
gastric carcinomas with distal or total gastrectomy and lymphadenectomy [18, 20].
4. Gastric gastrointestinal stromal tumours (GISTs)
GISTs are mesenchymal tumours that develop from the interstitial cells of Cajal (gastrointes-
tinal pacemakers) anywhere in the GI tract. GISTs are rare constituting only less than 1% of 
all GI malignancies. Although the annual reported incidence is just 10 cases per million, the 
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actual Incidence is believed to be much higher [22]. The stomach is the most common location 
for GISTs (70%). The driving force for GIST development is a gain-of-function mutation in 
tyrosine kinase receptor gene c-KIT [21].
Although the discovery of tyrosine kinase inhibitor imatinib has been the most significant 
change in GIST treatment over recent years, surgery as the only potentially curative method 
remains the cornerstone of treatment [23].
Gastric GISTs start their growth in deeper layers, mostly in the smooth muscle layer of gastric 
wall; expand intra- or extraluminally and eventually produce haematogenous metastasis in 
solid organs or peritoneum. They can also cause sarcomatosis by perforating into peritoneal 
cavity [21].
Any patient who is medically fit should undergo complete surgical resection of gastric GIST. 
However, NCCN and ESMO guidelines recommend endoscopic surveillance for small (<1 cm 
and <2 cm, respectively) gastric lesions if high-risk features are not present by endoscopic 
ultrasound investigation (ulcerations (see Figure 11), cystic spaces, irregular borders, echo-
genic foci and heterogeneity). All other cases and patients who do not want to undergo endo-
scopic surveillance should be treated by surgical resection [21, 24].
Unlike for carcinoma, a wide resection margin of healthy tissue is not necessary for GISTs. 
It is of paramount importance to be meticulous and remove the entire lesion without 
damaging tumour pseudocapsule or causing tumour spillage or bleeding as this would 
increase the risk of locoregional recurrence and sarcomatosis. GISTs rarely spread via lym-
phatics; therefore, lymphadenectomy is not necessary. If noted, enlarged lymph nodes 
near the tumour can selectively be dissected. Either wedge resection or full-thickness par-
tial gastrectomy is usually sufficient for lesser and greater curvature tumours, whereas a 
transgastric resection after anterior gastrotomy incision is performed for posterior wall 
gastric GISTs. Total or subtotal gastrectomy is only required for tumours occupying large 
portions of the stomach. If the tumour is borderline resectable or a extensive operation 
Figure 11. Gastrointestinal stromal tumour. Note the umbilicated ulceration.
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(total gastrectomy, en bloc resection of adjacent organs) is predicted, neoadjuvant treat-
ment with imatinib is used to downstage the tumour and perform less extensive surgery 
in advanced cases [21–24].
Laparoscopic surgery is considered a feasible and safe option for the treatment of small 
(<5 cm) gastric GISTs as long as the general oncologic principles are followed. This statement 
is supported by evidence from several retrospective cohort studies [23]. Direct manipula-
tion of the tumour with instruments is contraindicated, and a plastic bag must be used on 
extraction to reduce the risk of spillage. Both ESMO and NCCN guidelines support the use 
of laparoscopic technique for small gastric GISTs (<5 cm) [23]. Although there are studies that 
indicate feasibility for larger tumours [25], more high-quality research is needed to widen this 
indication. A hybrid procedure, endoscopy-assisted laparoscopic resection, can aid in tumour 
localisation and preservation of gastric volume. While it is currently performed in a limited 
amount of centres, it will probably take a more prominent place amongst minimally invasive 
gastric procedures [21].
5. Conclusions
Gastric cancer at present remains one of the most difficult oncological problems the surgeon 
has to deal with. Despite extensive research in novel systemic therapeutic options, surgery 
is still the only potentially curative treatment. Accumulation of evidence has made surgical 
treatment of gastric cancer more personalised allowing to select the extent of resection and 
lymphadenectomy according to specific tumour. Increased skills combined with technolog-
ical advances have further improved the postoperative function by making minimally inva-
sive approach safe and effective. Even complex procedures like D2 lymph node dissection 
are nowadays performed laparoscopically in specialised centres. Despite being rare, gastric 
NETs and GISTs need special consideration when it comes to surgical treatment because 
these tumours differ from adenocarcinomas in biology and best management. Robotic sur-
gery and hybrid endoscopic surgical procedures will probably have a more prominent role 
in the future because of their potential advantages over conventional laparoscopic surgery.
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